Watch the key takeaways in prostate cancer from ASCO20 Virtual by Professor Eric Small.

Do patients with non-metastatic castration-resistant prostate cancer exist or do they all have metastases if submitted to a PET scan? See Eric J. Small’s MEDtalk and hear his thoughts on the matter.

Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung cancer.

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study describes what characterizes the group of patients with non-metastatic castration-resistant prostate cancer.

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with non-metastatic castration-resistant prostate cancer.

The anti-PD-L1 checkpoint inhibitor pembrolizumab has shown long-term clinical efficacy as first-line treatment in metastatic non-small cell lung cancer, as monotherapy for PD-L1-positive tumors and in combination with chemotherapy regardless of PD-L1 status.

#Siste magasin

Onkologi / Hematologi

Nr. 2 • mars 2020
10. Årgang
  • Pancreas cancer
  • Meningeom
  • Livmorhalskreft

ASCO20 Virtual

Special Issue

Updates on COVID-19

ASH 2019

EHA 2019

ESMO 2019

ASCO 2019

#

Onkologi /hematologi

Anders Waage,

Anders Waage,
Overlege, Professor II

Daniel Heinrich,

Daniel Heinrich,
Overlege

Erik Skaaheim Haug,

Erik Skaaheim Haug,
Overlege, dr.med.

Jan Oldenburg,

Jan Oldenburg,
MD, ph.d., overlege

Jürgen Geisler,

Jürgen Geisler,
Professor, dr.med., dr. philos.

Odd Terje Brustugun,

Odd Terje Brustugun,
Overlege, dr.med.

Åse Bratland,

Åse Bratland,
Overlege, ph.d.,
fagansvarlig overlege